Member Login
  1. Stocks
    2. /
  2. AstraZeneca PLC (LSE: AZN)
    3. /

LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
Financial Market Data copyright © 2024 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

    • AstraZeneca PLC (LSE: AZN) Latest News

    Young Caucasian girl showing and pointing up with fingers number three against yellow background
    Investing Articles

    These three FTSE 100 stocks have huge upside

    | Ryan Hogg

    Ryan Hogg identifies a trio of FTSE 100 stocks that not only pay a dividend yield of more than 2%…

    Read more »

    Mature Caucasian woman sat at a table with coffee and laptop while making notes on paper
    Investing Articles

    Here’s the AstraZeneca dividend forecast for 2023

    | Edward Sheldon, CFA

    Here, Edward Sheldon looks at the AstraZeneca dividend forecast for this year with the pharma giant slowly increasing its dividend…

    Read more »

    Female Doctor In White Coat Having Meeting With Woman Patient In Office
    Investing Articles

    Earnings: why AstraZeneca shares are climbing

    | Alan Oscroft

    AstraZeneca shares have stormed ahead as the company's long-term rebuild is delivering revenue growth. Results for 2022 are here.

    Read more »

    Middle-aged white man pulling an aggrieved face while looking at a screen
    Investing Articles

    These were the FTSE 100’s biggest flops in January!

    | Cliff D'Arcy

    The FTSE 100 index had a good January, rising by 4.3%. While the shares of 86 Footsie firms rose last…

    Read more »

    Page

    Top UK Large-Cap Stocks of 2024

    | Zaven Boyrazian, MSc

    UK large-cap, or large-capitalisation, stocks are some of the most common in investors’ portfolios. These are the largest companies on…

    Read more »

    Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
    Investing Articles

    Tempted by the AstraZeneca share price? Here’s why it could explode in 2023

    | Charlie Carman

    The AstraZeneca share price has more than doubled over five years. Our writer outlines why the FTSE 100 healthcare stock…

    Read more »

    Inflation in newspapers
    Investing Articles

    2 inflation-resistant stocks I’d like to buy right now

    | Ben McPoland

    These two firms are on my 'stocks to buy' list for when I have more cash to invest. Both seem…

    Read more »

    Investing Articles

    3 ‘no-brainer’ FTSE 100 shares I’d buy for 2023

    | Harshil Patel

    FTSE 100 top picks! Our writer considers diversification, resilience and business quality to find the best shares for his ISA…

    Read more »

    Middle-aged white man pulling an aggrieved face while looking at a screen
    Investing Articles

    Revealed! The most sold FTSE 100 stocks by Hargreaves Lansdown investors

    | Royston Wild

    Demand for these FTSE 100 stocks sank among Hargreaves Lansdown clients this year. But could they rebound in 2023?

    Read more »

    Investing Articles

    Are AstraZeneca shares a growth buy for 2023?

    | Roland Head

    AstraZeneca's surging share price has made it the most valuable business in the FTSE 100. Roland Head analyses what's next…

    Read more »

    Investing Articles

    Top 2 FTSE 100 shares to buy for 2023

    | Harshil Patel

    2023 FTSE 100 top picks are here! Our writer takes an early look at the best shares to buy for…

    Read more »

    Young female business analyst looking at a graph chart while working from home
    Investing Articles

    If I’d invested £500 in AstraZeneca shares 2 years ago, here’s how much I’d have now!

    | Dr. James Fox

    Dr James Fox explores whether AstraZeneca shares are right for his portfolio after two years of strong share-price growth.

    Read more »